| 1 |
杨毅, 邱海波. 打赢新型冠状病毒感染肺炎疫情阻击战: 重症医学必须走在前面 [J/OL]. 中华重症医学电子杂志, 2020, 6(1): 27-28.
|
| 2 |
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet, 2020, 395(10223): 497-506.
|
| 3 |
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [J]. JAMA, 2020, 323(11): 1061-1069.
|
| 4 |
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [J]. Lancet Respir Med, 2020, 8(5): 475-481.
|
| 5 |
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [J]. Lancet, 2020,395(10224):565-574.
|
| 6 |
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [J]. Lancet Respir Med, 2020, 8(4): 420-422.
|
| 7 |
Skariyachan S, Challapilli SB, Packirisamy S, et al. Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for middle east respiratory syndrome coronavirus infections [J]. Front Microbiol, 2019,10:569.
|
| 8 |
Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study [J]. Lancet, 2020, 395(10225):689-697.
|
| 9 |
Imai Y, Kuba K, Ohto-Nakanishi T, et al. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis [J]. Circ J, 2010,74(3):405-410.
|
| 10 |
Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury [J]. Nat Med, 2005,11(8):875-879.
|
| 11 |
Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure [J]. Nature, 2005,436(7047):112-116.
|
| 12 |
Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients [J]. N Engl J Med, 2020, 382(12): 1177-1179.
|
| 13 |
管向东. "奉命于病难之间, 受任于疫虐之际"的重症医学—从新型冠状病毒肺炎, 思考重症学科发展[J/OL]. 中华重症医学电子杂志, 2020, 6(1): 23-24.
|
| 14 |
Hill AA, Diehl GE. Identifying the patterns of pattern recognition receptors [J]. Immunity, 2018, 49(3):389-391.
|
| 15 |
Goo J, Jeong Y, Park YS, et al. Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein [J]. Virus Res, 2020, 278:197863.
|
| 16 |
中华医学会重症医学分会, 中国医师协会重症医学医师分会, 中国病理生理学会危重病医学专业委员会. 重症新型冠状病毒肺炎管理专家推荐意见 [J/OL]. 中华重症医学电子杂志, 2020, 6(1): E026.
|
| 17 |
Yoshikawa N, Yoshikawa T, Hill T, et al. Differential virological and immunological outcome of severe acute respiratory syndrome coronavirus infection in susceptible and resistant transgenic mice expressing human angiotensin-converting enzyme 2 [J]. J Virol, 2009,83 (11): 5451-5465.
|
| 18 |
Xu J, Jia W, Wang P, et al. Antibodies and vaccines against Middle East respiratory syndrome coronavirus[J]. Emerg Microbes Infect, 2019,8 (1): 841-856.
|
| 19 |
刘军. 对全身性感染免疫与炎症关系的思考 [J].中华急诊医学杂志, 2017, 26 (11): 1230-1235.
|
| 20 |
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology [J]. Semin Immunopathol, 2017, 39 (5): 529-539.
|
| 21 |
刘军. 脓毒症免疫调节治疗的共识与争议 [J].中华医学杂志, 2019, 99 (45): 3597-3600.
|